Day: August 5, 2021

        Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancerLibtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death Trial enrolled patients with locally advanced and metastatic disease with squamous or non-squamous histology, and across all PD-L1 expression levels Libtayo has now demonstrated improved overall survival as a monotherapy or in combination with chemotherapy in first-line advanced non-small cell lung cancerPARIS and TARRYTOWN, NY – August 5, 2021 – The Phase 3 trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting...

PORTSMOUTH, N.H., Aug. 05, 2021 (GLOBE NEWSWIRE) — Sprague Resources LP (“Sprague”) (NYSE: SRLP) today reported its financial results for the second quarter ended June 30, 2021. Second Quarter 2021 HighlightsNet sales were $657.7 million for the second quarter of 2021, compared to net sales of $358.2 million for the second quarter of 2020. GAAP net loss was $45.6 million for the second quarter of 2021, compared to net loss of $25.1 million for the second quarter of 2020. Adjusted gross margin* was $38.8 million for the second quarter of 2021, compared to adjusted gross margin of $65.2 million for the second quarter of 2020. Adjusted EBITDA* was $3.0 million for the second quarter of 2021, compared to adjusted EBITDA of $28.0 million for the second quarter of 2020.“While second quarter results were weaker than last year’s...

Second-Quarter HighlightsRevenue increased 19.3% on net sales of $99.7 million Gross margin declined 267 basis points to 25.2% Operating income of $10.7 million vs. $10.9 million in the second quarter of 2020 Diluted EPS of $0.58 per shareEVANSVILLE, Ind., Aug. 05, 2021 (GLOBE NEWSWIRE) — Escalade, Incorporated (NASDAQ: ESCA) – today announced its second quarter results for 2021, ended July 10, 2021. The Company posted quarterly revenue of $99.7 million, an increase of 19.3% over prior year, posting another record for its second fiscal quarter. Quarterly diluted earnings per share were $0.58. “Second quarter results reflect strong demand for our products, offset by sharply higher raw material costs, increased wage pressure, and inventory handling costs. Global supply chain issues persist as our logistics team works to keep...

HOOKIPA’s arenaviral platform technology demonstrated ability to modulate the tumor microenvironment and induce potent melanoma-specific T cell responsesA single, intra-tumoral injection of the arenaviral immunotherapeutic resulted in tumor regression in all mice and tumor cures in about 60 percent of recipientsPublication adds to the growing body of evidence supporting the potential of HOOKIPA’s novel arenaviral therapeutics in cancerNEW YORK and VIENNA, Austria, Aug. 05, 2021 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that pre-clinical data on its replicating Lymphocytic choriomeningitis (LCMV) arenaviral-based immunotherapeutic has been published in the peer-reviewed journal, Nature...

Fan Pass is in the music category of both stores, encompassing billions of users CAMPBELL, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Friendable Inc. (OTC: FDBL), a mobile technology and marketing company, is pleased to announce the approval of the Fan Pass livestream artist platform by both the Apple App and Google Play Stores. The mobile applications can now be downloaded by users worldwide, and Fan Pass is also accessible via desktop and web applications. “Today, we achieve a tremendous milestone as we welcome our existing artists and fans to an entirely new platform and experience and prepare to push the Fan Pass brand to the masses with our next set of marketing and awareness initiatives. Collectively, our team, artists, fans, partners and shareholders have delivered valuable insights, which have produced...

A Media Snippet accompanying this announcement is available by clicking on the image or link below:VANCOUVER, British Columbia, Aug. 05, 2021 (GLOBE NEWSWIRE) — Extreme Vehicle Battery Technologies Corp. (the “Company” or “EV Battery Tech”) (CSE: ACDC) is pleased to announce the launch of its IoniX Pro Trilogy Vision Electric Vehicle (EV) line which is being developed in collaboration with Daymak International Inc. (“Daymak”), further to its partnership agreement announced on February 8, 2021 and the new amending agreement announced August 4, 2021 which granted EV Battery Tech and IoniX Pro Battery Technologies Inc. (“IoniX Pro”), exclusive worldwide rights to build an EV based on the Daymak Spiritus. Click Here for Video The IoniX Pro Trilogy Vision and Vision X (together, the “Trilogy Line”) are expected to be powered by the...

Company announcement – No. 49 / 2021 Zealand Pharma Hosts Conference Call on August 12 at 4 pm CET (10am ET) to Present Second Quarter Results for 2021 Copenhagen, DK and Boston, MA, U.S. August 5, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that it will host a conference call on August 12, 2021 at 4 pm CET (10 am ET) following the announcement of results for the second quarter of 2021. Presenting during the call will be President and Chief Executive Officer Emmanuel Dulac, Senior Vice President and Chief Financial Officer Matt Dallas, and Executive Vice President, and Chief Medical Officer Adam Steensberg. The presentation will be followed by a Q&A session with presenters and...

Terms for switches to inflation-linked bond SGB IL 3115 The Swedish National Debt Office will offer switches to government bond SGB IL 3115 from SGB IL 3111, SGB IL 3114 and SGB IL 3104 during the period 3 September – 7 September. The total volume offered of SGB IL 3115 is SEK 3.75 billion. The switches are offered to build up the outstanding volume of SGB IL 3115. The switches will be made price risk neutral1 as well as cash neutral2.Switch auctions  Fri 3 Sept Risk neutral Mon 6 Sept Risk neutral Tue 7 Sept Cash neutralSNDO sells bond 3115 3115 3115SNDO sells amount (SEK mn) 3 1 500 1 250 1 000SNDO buys bond 3111 3114 3104SNDO buys amount (SEK mn) 2 400 2 700 700Time for yield on buy-back bond 10.45 10.45 10.45Time for auction cut-off 11.00 11.00 11.00Time for auction result 11.03 11.03 11.03The dates for...

Company Announcement no. 13/2021This company announcement contains inside information   The Board of Directors for Wirtek A/S raises the financial expectations for the second time this year based on preliminary financial results for Q2 2021 and an updated prognosis for second half of 2021.  The integration of the CoreBuild acquisition is progressing very well. The financial results of Wirtek’s organic business for the first 6 months of 2021 combined with the financial results of the first month of CoreBuild business exceeds our expectations. Additionally, the current outlook for the combined business for second half of 2021 also exceeds our expectations.  Consequently, the Board of Directors has decided to raise the expectations for 2021:   The revenue expectation is raised to DKK 44.5m – 45.5m (up from previously DKK 42.0m – 44.0m),...

HAMILTON, Ontario, Aug. 05, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed contracts with six new US primary care physician practices to provide its iUGO Care platform to their chronic disease patients. “We are pleased to announce that we are adding six new US physician practices and over 4,000 new patients to our iUGO Care platform,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “These primary care physician practices will be using our iUGO Care Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and Behavioural Health Integration (BHI) modules. The average...